Ad
related to: guillain barré syndrome clinical trials
Search results
Results from the WOW.Com Content Network
Guillain–Barré syndrome (GBS) is a rapid-onset muscle weakness caused by the immune system damaging the peripheral nervous system. [3] Typically, both sides of the body are involved, and the initial symptoms are changes in sensation or pain often in the back along with muscle weakness, beginning in the feet and hands, often spreading to the arms and upper body. [3]
The next morning he had generalised aches, the day after sharp abdominal pain and a fever increasingly raged. Bedridden in pain, he gradually lost the ability to move, to the point, 8 days later of just flickering his eyes or twitch his hands. His cognition was not affected. The symptoms all fit with Guillain–Barré syndrome. His minimal ...
Neurology. Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired autoimmune disease of the peripheral nervous system characterized by progressive weakness and impaired sensory function in the legs and arms. [1] The disorder is sometimes called chronic relapsing polyneuropathy (CRP) or chronic inflammatory demyelinating ...
An estimated 3,000 to 6,000 people develop Guillain-Barre syndrome in the U.S. each year — either after being infected by a virus or linked to a vaccination — and it’s more common in older ...
Immunoglobulin therapy is the use of a mixture of antibodies (normal human immunoglobulin) to treat several health conditions. [13] [14] These conditions include primary immunodeficiency, immune thrombocytopenic purpura, chronic inflammatory demyelinating polyneuropathy, Kawasaki disease, certain cases of HIV/AIDS and measles, Guillain–Barré syndrome, and certain other infections when a ...
A demyelinating disease refers to any disease affecting the nervous system where the myelin sheath surrounding neurons is damaged. [1] This damage disrupts the transmission of signals through the affected nerves, resulting in a decrease in their conduction ability. Consequently, this reduction in conduction can lead to deficiencies in sensation ...
Specialty. Neurology. Acute motor axonal neuropathy (AMAN) is a variant of Guillain–Barré syndrome. It is characterized by acute paralysis and loss of reflexes without sensory loss. Pathologically, there is motor axonal degeneration with antibody-mediated attacks of motor nerves and nodes of Ranvier. [citation needed]
This presents with the classical triad of ataxia, areflexia and ophthalmoplegia. The clinical spectrum of disorders associated with anti-GQ1b now is also recognized to include, Bickerstaff brainstem encephalitis, Guillain-Barré syndrome with ophthalmoplegia, and acute ophthalmoplegia without ataxia. [11]
Ad
related to: guillain barré syndrome clinical trials